

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/931,071		08/15/2001	John Bertin	07334-335001 / MPI99-258C	2948
26161	7590	04/24/2003		•	
FISH & RI		SON PC	EXAMINER		
225 FRANKLIN ST BOSTON, MA 02110				· MCGARRY, SEAN	
				ART UNIT	PAPER NUMBER
				1635	
				DATE MAILED: 04/24/2003	10

Please find below and/or attached an Office communication concerning this application or proceeding.

,		Application No.	Applicant(s)
		09/931,071	BERTIN ET AL.
	Office Action Summary	Examiner	Art Unit
		Sean R McGarry	1635
Period fo	The MAILING DATE of this communication apor Reply		I
THE - Exte after - If the - If NC - Failu - Any	ORTENED STATUTORY PERIOD FOR REPL MAILING DATE OF THIS COMMUNICATION. nsions of time may be available under the provisions of 37 CFR 1. SIX (6) MONTHS from the mailing date of this communication. It is period for reply specified above is less than thirty (30) days, a replayment of the provision of the period for reply is specified above, the maximum statutory period reto reply within the set or extended period for reply will, by statutively received by the Office later than three months after the mailing aparent term adjustment. See 37 CFR 1.704(b).	136(a). In no event, however, may a repoly within the statutory minimum of thirty (will apply and will expire SIX (6) MONTH e. cause the application to become ABA	ly be timely filed  30) days will be considered timely.  35 from the mailing date of this communication.
1)	Responsive to communication(s) filed on	·	
2a) <u></u>		his action is non-final.	
3) <u></u> Dispositi	Since this application is in condition for allow closed in accordance with the practice under on of Claims	rance except for formal matter Ex parte Quayle, 1935 C.D.	ers, prosecution as to the merits is 11, 453 O.G. 213.
4)⊠	Claim(s) 1-17 is/are pending in the application	n.	
	4a) Of the above claim(s) is/are withdra	wn from consideration.	
5)	Claim(s) is/are allowed.		
6)□	Claim(s) is/are rejected.		
7)	Claim(s) is/are objected to.		
8)⊠	Claim(s) 1-17 are subject to restriction and/or	election requirement.	
Applicati	on Papers		
9)[	Γhe specification is objected to by the Examine	er.	
10) 🔲 🗆	「he drawing(s) filed on is/are: a)□ acce	pted or b)□ objected to by the	Examiner.
	Applicant may not request that any objection to the	e drawing(s) be held in abeyand	ce. See 37 CFR 1.85(a).
11) 🔲 7	he proposed drawing correction filed on	_ is: a)∏ approved b)∏ disa	approved by the Examiner.
_	If approved, corrected drawings are required in re		
12) 🗌 7	he oath or declaration is objected to by the Ex	aminer.	
Priority u	nder 35 U.S.C. §§ 119 and 120		
13)[	Acknowledgment is made of a claim for foreigr	n priority under 35 U.S.C. § 1	19(a)-(d) or (f).
a)[	☐ All b)☐ Some * c)☐ None of:		
	<ol> <li>Certified copies of the priority document</li> </ol>	s have been received.	
	<ol><li>Certified copies of the priority document</li></ol>	s have been received in App	lication No
	<ol> <li>Copies of the certified copies of the prior application from the International Bu ee the attached detailed Office action for a list</li> </ol>	reau (PCT Rule 17.2(a)).	_
_	cknowledgment is made of a claim for domesti	•	
a)	☐ The translation of the foreign language procknowledgment is made of a claim for domesti	visional application has beer	received.
1) Notice 2) Notice 3) Inform	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-948) ation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Info	nmary (PTO-413) Paper No(s) rmal Patent Application (PTO-152)
.S. Patent and Tra PTO-326 (Rev	* 4 * 4 * 5	tion Summary	Part of Paper No. 10

Application/Control Number: 09/931,071 Page 2

Art Unit: 1635

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-10, drawn to a method of identifying a compound that modulates interaction between CARD-8 andcaspase-1, pseudo-ICE, or ICEBERG via detection of binding in presence of a test compound., classifiable in class 435, subclass 7.1.
- II. Claims 11-14, drawn to a method of identifying a compound that modulates an activity of CARD-8 via contacting CARD-8 with a test compound and determining effect on CARD-8 activity, classifiable in class 435, subclass 7.1.
- III. Claim 16, drawn to a method of treating a disorder associated with inappropriate apoptosis via the modulation of CARD-8 activity or expression, classifiable in class 514, subclass 44.
- IV. Claim 16, drawn to a method of treating a disorder associated with inappropriate inflammation via the modulation of CARD-8 activity or expression, classifiable in class 514, subclass 44.
- V. Claim 17, drawn to a method of treating a disorder associated with inappropriate apoptosis comprising the modulation of CARD-7 activity or expression, classifiable in class 514, subclass 44.

Application/Control Number: 09/931,071

Art Unit: 1635

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are different methods to determine different interactions. For example, the method of Group I is drawn to the modulation of the binding of specific proteins where there is no requirement for any modulation of activity. The method of group II is drawn to a method of finding modulators of activity of CARD-8, which does not require the modulation of binding to the specific proteins of Group I, for example.

Inventions (I-IV) and V are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions of Groups I-IV all require the use of CARD-8 protein or CARD-8 modulation and not CARD-7 and the method of Group V requires the use of CARD-7 and does not require CARD-8. The methods would appear to be mutually exclusive.

Inventions IV and III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are method of treating different

Application/Control Number: 09/931,071

Art Unit: 1635

diseases/disorders that have different pathologies, which would require materially different compounds and method steps, for example.

Inventions (III and IV) and (I and II) are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are different methods that have different method steps where the method steps lead to different ends. The methods of (I and II) are drawn to finding modulators while the method of III and IV are drawn to treating disease, for example.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sean R McGarry whose telephone number is (703) 305-7028. The examiner can normally be reached on M-Th (6:00-4:30).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John LeGuyader can be reached on (703) 308-0447. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4242 for regular communications and (703) 872-9307 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

SRM April 22, 2003

SEAN MCGARRY PRIMARY EXAMINER